Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: The need for standardization in clinical practice
Open Access
- 16 February 2010
- journal article
- research article
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 23 (8) , 820-827
Abstract
Objective. The importance of an anti-angiogenic state as a mechanism of disease in preeclampsia is now recognized. Assays for the determination of concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-1, sVEGFR-2, placental growth factor (PlGF) and soluble endoglin (sEng) have been developed for research and clinical laboratories. A key question is whether these factors should be measured in plasma or serum. The purpose of this study was to determine if there are differences in the concentrations of these analytes between plasma and serum in normal pregnancy and in preeclampsia. Methods. Samples of maternal blood were obtained by venipuncture and collected in EDTA (lavender top) and serum collection tubes (red top). A standard laboratory procedure was implemented for the centrifugation, aliquoting and storage of samples. Plasma and serum from 70 women with normal pregnancies and 34 patients with preeclampsia were assayed for sVEGFR-1, sVEGFR-2, PlGF and sEng by ELISA. Nonparametric paired tests were used for analyses. Results. A significant difference between plasma and serum concentration was observed for sVEGFR-1 and sVEGFR-2 in normal pregnancy, and for sVEGFR-1, sVEGFR-2, PlGF and sEng in women with preeclampsia. Conclusion. The concentrations of sVEGFR-1, sVEGFR-2, PlGF and sEng when measured in maternal plasma and in serum are different. Therefore, the matrix used for the assay (serum versus plasma) needs to be considered when selecting thresholds for predictive studies and interpreting the growing body of literature on this subject.Keywords
This publication has 87 references indexed in Scilit:
- A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsiaThe Journal of Maternal-Fetal & Neonatal Medicine, 2009
- Prediction of Preeclampsia – A Workshop ReportPlacenta, 2008
- Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusionAmerican Journal of Obstetrics and Gynecology, 2008
- The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational ageThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- Second-trimester angiogenic factors as biomarkers for future-onset preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2007
- Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2007
- Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factorAmerican Journal of Obstetrics and Gynecology, 2007
- Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia developAmerican Journal of Obstetrics and Gynecology, 2004
- Diagnosis and management of preeclampsia and eclampsiaInternational Journal of Gynecology & Obstetrics, 2002